2022
Comparative outcomes for mature T-cell and NK/T-cell lymphomas in people with and without HIV and to AIDS-defining lymphomas
Koh MJ, Merrill MH, Koh MJ, Stuver R, Alonso CD, Foss FM, Mayor AM, Gill J, Epeldegui M, Cachay E, Thorne JE, Silverberg MJ, Horberg MA, Althoff K, Nijhawan AE, McGinnis KA, Lee JS, Rabkin CS, Napravnik S, Li J, Castilho JL, Shen C, Jain S. Comparative outcomes for mature T-cell and NK/T-cell lymphomas in people with and without HIV and to AIDS-defining lymphomas. Blood Advances 2022, 6: 1420-1431. PMID: 35026839, PMCID: PMC8905704, DOI: 10.1182/bloodadvances.2021006208.Peer-Reviewed Original ResearchConceptsT-cell lymphomaAnaplastic large cell lymphomaB-cell lymphomaHodgkin's lymphomaNorth American AIDS Cohort CollaborationNK/T-cell lymphomaPrimary central nervous system lymphomaModern antiretroviral therapy (ART) eraCentral nervous system lymphomaLarge B-cell lymphomaAntiretroviral therapy eraComprehensive Oncology MeasuresMature T-cell lymphomasNervous system lymphomaLarge cell lymphomaT-cell malignanciesMature T cellsCohort CollaborationTherapy eraOverall survivalSystem lymphomaHistologic confirmationLymphoma treatmentT cellsComparative outcomes
2021
Novel Single Agents Are Equivalent to Conventional Chemotherapy Inpatients with Relapsed and Refractory Mature T-Cell Lymphomas: A Meta-Analysis
Shafagati N, Stuver R, Boussi L, Koh M, Park A, Bain P, Foss F, Shen C, Jain S. Novel Single Agents Are Equivalent to Conventional Chemotherapy Inpatients with Relapsed and Refractory Mature T-Cell Lymphomas: A Meta-Analysis. Blood 2021, 138: 1431. DOI: 10.1182/blood-2021-150315.Peer-Reviewed Original ResearchOverall response rateT-cell lymphomaHistological subtypesNovel single agentsSingle agentHistone deacetylase inhibitorsConventional chemotherapyResponse rateCentral RegisterPartial responsePTCL-NOSClinical trialsChemotherapy agentsComparable overall response ratesGeneric inverse variance methodCutaneous T-cell lymphomaPhase IParticular histological subtypeSpeakers bureauCochrane Central RegisterProgression-free survivalMature T-cell lymphomasPI3K/Akt/mTORDuration of responseInverse variance methodComparative Analysis of Mature T-Cell and NK/T-Cell Lymphomas in Patients with and without HIV: Results from the NA-Accord and Complete Cohorts
Koh M, Merrill M, Koh M, Stuver R, Alonso C, Foss F, Mayor A, Gill M, Epeldegui M, Cachay E, Thorne J, Silverberg M, Horberg M, Atlhoff K, Nijhawan A, McGinnis K, Rabkin C, Napravnik S, Shen C, Jain S. Comparative Analysis of Mature T-Cell and NK/T-Cell Lymphomas in Patients with and without HIV: Results from the NA-Accord and Complete Cohorts. Blood 2021, 138: 1380. DOI: 10.1182/blood-2021-147837.Peer-Reviewed Original ResearchNK/T-cell lymphomaT-cell lymphomaB-cell lymphomaNA-ACCORDViral loadBurkitt's lymphomaLymphoma diagnosisCurrent antiretroviral therapy eraWorse median overall survivalPeripheral T-cell lymphomaAnaplastic large cell lymphomaLarge B-cell lymphomaAntiretroviral therapy eraBaseline clinical characteristicsMedian overall survivalMulticenter cohort studyOutcomes of patientsSpeakers bureauChronic kidney diseasePrimary CNS lymphomaYear of diagnosisCommon histological subtypeMature T-cell lymphomasSurvival of patientsLarge observational cohort
2010
Current and Emerging Treatment Strategies for Cutaneous T-cell Lymphoma
Lansigan F, Foss FM. Current and Emerging Treatment Strategies for Cutaneous T-cell Lymphoma. Drugs 2010, 70: 273-286. PMID: 20166766, DOI: 10.2165/11532190-000000000-00000.Peer-Reviewed Original ResearchConceptsCutaneous T-cell lymphomaT-cell lymphomaMalignant T cellsTreatment strategiesT cellsManagement of CTCLPredictable adverse effectsRapid disease controlConservative treatment strategyFront-line therapyEarly-stage diseaseIndolent clinical courseMature T-cell lymphomasStem cell transplantInterleukin-2 receptorHistone deacetylase inhibitorsSystemic chemotherapyExtracorporeal photopheresisInitial managementSézary syndromeClinical courseCurative therapyBiological therapyCell transplantMycosis fungoides